Aevi Genomic Medicine (GNMX) Misses Q1 EPS by 2c; to Initiate Phase 2 Trial of AEVI-001

Aevi Genomic Medicine (NASDAQ: GNMX) reported Q1 EPS of ($0.29), $0.02 worse than the analyst estimate of ($0.27).

• Company to initiate a Phase 2 clinical trial in 2H 2017, targeting a specific genetic subset of patients identified by a responder analysis of the SAGA trial
• Responder subset is approximately 10% of the US pediatric ADHD population and a total addressable market of $2 to $3 billion
• Genetic subset had a 90% response rate and stimulant-like effect in the SAGA trial
• Patients with the most commonly mutated gene, CNTN4, demonstrated a more severe phenotype and highest response to therapy in SAGA trial
• Patient recruitment for AEVI-002 in Severe Pediatric Onset Crohn's Disease to begin during 2Q 2017

For earnings history and earnings-related data on Aevi Genomic Medicine (GNMX) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Hydrofarm Holdings Group, Inc. (HYFM) Misses Q2 EPS by 134c
• Zeo Energy Corp (ZEO) Misses Q2 EPS by 7c